Arkadios Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Arkadios Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.65M	Sell	3,684 -281	-7%	-$131K	0.03%	590
2025 Q4	$1.8M	Buy	3,965 +1,631	+70%	+$703K	0.03%	483
2025 Q3	$914K	Buy	2,334 +182	+8%	+$76.1K	0.02%	677
2025 Q2	$958K	Buy	2,152 +697	+48%	+$321K	0.03%	588
2025 Q1	$706K	Buy	1,455 +374	+35%	+$174K	0.03%	583
2024 Q4	$435K	Buy	1,081 +410	+61%	+$190K	0.02%	601
2024 Q3	$312K	Buy	+671	New	+$322K	0.02%	694
2021 Q4	–	Sell	-121	Closed	-$21K	–	1756
2021 Q3	$21K	Buy	121 +21	+21%	+$4.1K	﹤0.01%	1202
2021 Q2	$20K	Buy	+100	New	+$20.9K	﹤0.01%	1299
2020 Q2	–	Sell	-4	Closed	-$952	–	1154
2020 Q1	$952	Buy	+4	New	+$918	﹤0.01%	971

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arkadios Wealth Advisors's VRTX Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 7.1% in Q1 2026, selling an estimated $131K and leaving 3,684 shares worth $1.65M. The position accounts for 0.03% of the portfolio, ranked #590.

Arkadios Wealth Advisors first reported a position in VRTX in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.8M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Arkadios Wealth Advisors held 3,684 shares of Vertex Pharmaceuticals worth $1.65M as of Q1 2026.
Arkadios Wealth Advisors sold 281 Vertex Pharmaceuticals shares in Q1 2026, an estimated $131K.
Vertex Pharmaceuticals made up 0.03% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #590 holding.
Arkadios Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
Arkadios Wealth Advisors's Vertex Pharmaceuticals position peaked at $1.8M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.